Richard Bryce, MBChB, MRCGP, MFPM
Chief Medical and Scientific Officer
Dr. Bryce joined Puma Biotechnology as Senior Vice President, Clinical R&D on June 20, 2012. He
became our Chief Medical and Scientific Officer in August 2017. From 2008 to 2012, he was employed
at Onyx Pharmaceuticals where, as clinical lead, he oversaw the sorafenib Phase II breast and colorectal
cancer programs and the carfilzomib Phase III multiple myeloma program. Previous appointments
include International Medical Leader at Roche for Xeloda® in breast cancer, and senior positions at ICON
Clinical Research, ILEX and Scotia Pharmaceuticals, where he was the lead clinician on successful
registration studies for Campath® in CLL and multiple sclerosis, and Foscan®-PDT for squamous cell head
and neck cancer.
Dr. Bryce received his BSc (Medical Sciences) and MBChB degrees from the University of Edinburgh,
Scotland, in 1978 and 1981. Postgraduate board certifications include those from the Royal College of
General Practitioners of the UK and Royal College of Physicians (Faculty of Pharmaceutical Medicine).
Dr. Bryce is a member of the American Society of Clinical Oncology, American Society of Hematology
and the European Society of Medical Oncology.
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024